Keyword Tag Sort by

Retinal vein occlusion News (5 articles)



New data for Novartis drug Lucentis® confirms long-term efficacy and safety profile and benefits of individualized treatment

REPAIR study shows an average of three Lucentis® injections improve visual acuity in patients with myopic choroidal neovascularization RESTORE extension study demonstrates DME patients fully maintained initial vision gains with an average of 13.9 Lucentis injections over three...

Published on 5 September 2012, 08:47


Novartis gains European Commission approval for Lucentis® to treat vision loss due to macular edema secondary to RVO

Lucentis (ranibizumab) is first anti-VEGF approved for visual impairment due to macular edema secondary to branch- and central-retinal vein occlusion (RVO) Pivotal clinical data show rapid and significant improvements in visual acuity at six months with Lucentis treatment...

Published on 6 June 2011, 06:45


Novartis gains positive CHMP opinion for Lucentis® (ranibizumab) to treat vision loss due to macular edema secondary to RVO

Lucentis recommended for approval in EU for visual impairment due to macular edema secondary to branch- and central-retinal vein occlusion (RVO) Pivotal data show rapid and significant improvements in visual acuity at six months with Lucentis treatment compared to standard...

Published on 18 March 2011, 09:40


Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion

Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients with swelling in the retina (macular edema) due to central retinal vein occlusion (RVO). Central RVO is a common cause of vision loss that occurs when blood flow through a...

Published on 30 July 2009, 13:25


Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion

Study Showed Early and Sustained Improvement in Vision Through Six MonthsBasel, 2 July 2009 - Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected...

Published on 2 July 2009, 12:50


image